Global Fluorescent In Situ Hybridization Probe Market Grows at a Steady CAGR of 7.64%

Introduction

Straits Research released its highly anticipated report, “Fluorescent In Situ Hybridization Probe Market Size & Outlook, 2026-2034.” According to the study, the global fluorescent in situ hybridization probe market size is valued at USD 1049.21 million in 2025 and is projected to expand to USD 2028.15 million by 2034, registering a compound annual growth rate (CAGR) of 7.64%.

Market Dynamics

The market growth is primarily attributed to the rising prevalence of cancer and genetic disorders, and the growing demand for personalized medicine. In addition, advancements in molecular diagnostic technologies, such as fluorescent in situ hybridization (FISH), have enhanced the accuracy, speed, and accessibility of genetic testing. These innovations have led to the development of more precise probes and automated systems, facilitating the widespread adoption of FISH in clinical settings, which further drives the adoption of advanced techniques to meet the growing demand for precise and personalized medical care. However, the high cost of FISH probes and equipment, which limits adoption, especially in developing regions and smaller laboratories, limits the market growth. Moreover, integration of FISH into liquid biopsy platforms offers a significant opportunity for market expansion. For example, in September 2025, an article published in the National Library of Medicine demonstrated the feasibility of combining FISH with liquid biopsy techniques to detect genetic mutations in plasma cell neoplasms. The study found that this integrated approach could identify mutations in genes from blood samples, offering a non-invasive method for genetic profiling and monitoring treatment response. Such advancement underscores the potential for FISH to play a pivotal role in the future of cancer diagnostics, offering a non-invasive, efficient, and comprehensive approach to genetic analysis.

Market Highlights

• Type: The RNA Probes segment is expected to register the fastest CAGR (8.97%) during the forecast period, driven by the increasing use in cancer diagnostics and advancements in molecular biology techniques, enhancing assay sensitivity and specificity.
• Technology: The Quantitative FISH segment dominated the market with a revenue share of 36.73%. 
• Application: The Cancer Diagnostics segment dominated the market in 2025 with a revenue share of 44.25%.
• End User: The companion diagnostics is expected to grow at the fastest pace with a CAGR of 9.07% during the forecast period.
• Regional Insights: North America dominated the market with a 23% share, driven by the advanced molecular diagnostic technologies and supportive government initiatives.

Competitive Players

1. Hoffmann-La Roche Ltd
2. Agilent Technologies, Inc.
3. Abbott
4. Thermo Fisher Scientific Inc.
5. Bio-Rad Laboratories, Inc.
6. Genemed Biotechnologies, Inc.
7. Oxford Gene Technology IP Limited
8. Biosearch Technologies
9. Merck KGaA
10. QIAGEN
11. PerkinElmer, Inc.
12. BioDot
13. Abnova Corporation
14. Biocare Medical, LLC. 
15. Daicel Arbor Biosciences
16. Precision Medicine Group, LLC
17. Cell Culture Company, LLC
18. Advanced Cell Diagnostics, Inc.
19. BioGenex.
20. Leica Biosystems Nussloch GmbH 
21. Others

Recent Developments

Segmentation

1. By Type (2026-2034)
   1. DNA Probes
   2. RNA Probes
2. By Technology (2026-2034)
   1. Quantitative FISH
   2. Multiplex FISH
   3. Conventional FISH
3. By Application (2026-2034)
   1. Cancer Diagnostics
   2. Genetic Diseases
   3. Cytogenetics
   4. Other
4. By End User (2026-2034)
   1. Research
   2. Clinical Use
   3. Companion Diagnostics